OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms

The bHLH transcription factor, OLIG2, is universally expressed in adult human gliomas and, as a major factor in the development of oligodendrocytes, is expressed at the highest levels in low-grade oligodendroglial tumors. In addition, it is functionally required for the formation of high-grade astrocytomas in a genetically relevant murine model. The pediatric gliomas have genomic profiles that are different from the corresponding adult tumors and accordingly, the expression of OLIG2 in non-oligodendroglial pediatric gliomas is not well documented within specific tumor types. In the current study, the pattern of OLIG2 expression in a spectrum of 90 non-oligodendroglial pediatric gliomas varied from very low levels in the ependymomas (cellular and tanycytic) to high levels in pilocytic astrocytoma, and in the diffuse-type astrocytic tumors (WHO grades II–IV). With dual-labeling, glioblastoma had the highest percentage of OLIG2 expressing cells that were also Ki-67 positive (mean = 16.3%) whereas pilocytic astrocytoma WHO grade I and astrocytoma WHO grade II had the lowest (0.9 and 1%, respectively); most of the Ki-67 positive cells in the diffuse-type astrocytomas (WHO grade II–III) were also OLIG2 positive (92–94%). In contrast to the various types of pediatric astrocytic tumors, all ependymomas WHO grade II, regardless of site of origin, showed at most minimal OLIG2 expression, suggesting that OLIG2 function in pediatric gliomas is cell lineage dependent.

[1]  H. Ng,et al.  Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas , 2000, Histopathology.

[2]  Q. Lu,et al.  The Basic Helix-Loop-Helix Transcription Factor Olig2 Is Critical for Reactive Astrocyte Proliferation after Cortical Injury , 2008, The Journal of Neuroscience.

[3]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[4]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Figarella-Branger,et al.  Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization , 2006, Oncogene.

[6]  Oscar Gonzalez-Perez,et al.  Origin of Oligodendrocytes in the Subventricular Zone of the Adult Brain , 2006, The Journal of Neuroscience.

[7]  S. Vandenberg,et al.  PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.

[8]  D. Rowitch,et al.  Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Wegner,et al.  Oligodendroglial-specific Transcriptional Factor SOX10 is Ubiquitously Expressed in Human Gliomas , 2005, Journal of Neuro-Oncology.

[10]  K. Wong,et al.  Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. , 2005, Cancer research.

[11]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[12]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[13]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[14]  M. Götz,et al.  Neuronal fate determinants of adult olfactory bulb neurogenesis , 2005, Nature Neuroscience.

[15]  B. Kleinschmidt-DeMasters,et al.  Unique Molecular Characteristics of Pediatric Myxopapillary Ependymoma , 2009, Brain pathology.

[16]  C. Godfraind.  Classification and controversies in pathology of ependymomas , 2009, Child's Nervous System.

[17]  Caterina Giannini,et al.  Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas , 2006, The American journal of surgical pathology.

[18]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[19]  Susanne Kneitz,et al.  Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival , 2007, Acta Neuropathologica.

[20]  P. Burger,et al.  Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma , 2008, Journal of neuropathology and experimental neurology.

[21]  Y. Ohba,et al.  Oligodendrocyte Lineage Transcription Factor 2 Inhibits the Motility of a Human Glial Tumor Cell Line by Activating RhoA , 2007, Molecular Cancer Research.

[22]  J. Goldman,et al.  GFAP and its role in Alexander disease. , 2007, Experimental cell research.

[23]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[24]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Goldman,et al.  Isolation of a major protein component of Rosenthal fibers. , 1988, The American journal of pathology.

[26]  T. Hirose,et al.  Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. , 2008, Clinical neuropathology.

[27]  C. Simopoulos,et al.  Loss of chromosome 1 in myxopapillary ependymoma suggests a region out of chromosome 22 as critical for tumour biology: a FISH analysis of four cases on touch imprint smears , 2006, Cytopathology : official journal of the British Society for Clinical Cytology.

[28]  Tiansen Li,et al.  Rootletin interacts with C-Nap1 and may function as a physical linker between the pair of centrioles/basal bodies in cells. , 2005, Molecular biology of the cell.

[29]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[30]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[31]  K. Wong,et al.  Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival , 2007, Journal of Neuro-Oncology.

[32]  Amar Gajjar,et al.  Cross-species genomics matches driver mutations and cell compartments to model ependymoma , 2010, Nature.

[33]  Arie Perry,et al.  Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. , 2002, Cancer research.

[34]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[35]  Hendrik Witt,et al.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma , 2009, Acta Neuropathologica.

[36]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[37]  Tiansen Li,et al.  Focus on molecules: rootletin. , 2006, Experimental eye research.

[38]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[39]  Douglas C. Miller,et al.  Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas , 2000, Brain pathology.

[40]  H. Ohgaki,et al.  Genetic pathways to glioblastomas , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[41]  J. A. van der Laak,et al.  Inverse Correlation between Genetic Aberrations and Malignancy Grade in Ependymal Tumors: A Paradox? , 2004, Journal of Neuro-Oncology.

[42]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[43]  Arie Perry,et al.  Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. , 2007, Cancer research.

[44]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[45]  Tiansen Li,et al.  Rootletin, a novel coiled-coil protein, is a structural component of the ciliary rootlet , 2002, The Journal of cell biology.

[46]  R. DePinho,et al.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.

[47]  I. Pollack,et al.  Expression of p53 and prognosis in children with malignant gliomas. , 2002, The New England journal of medicine.

[48]  T. Shaikh,et al.  Duplication of 7q34 in Pediatric Low‐Grade Astrocytomas Detected by High‐Density Single‐Nucleotide Polymorphism‐Based Genotype Arrays Results in a Novel BRAF Fusion Gene , 2009, Brain pathology.

[49]  J. Lowe,et al.  Pediatric Ependymoma: Biological Perspectives , 2009, Molecular Cancer Research.

[50]  Y. Sawamura,et al.  Expression of the Oligodendroglial Lineage‐Associated Markers Olig1 and Olig2 in Different Types of Human Gliomas , 2003, Journal of neuropathology and experimental neurology.

[51]  M. Watson,et al.  RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma , 2005, Neurology.

[52]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[53]  H. Budka,et al.  OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms , 2007, Histopathology.

[54]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.